Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 20,510 | 18,560 | 20,220 | 20,050 | 19,660 | 19,460 | 20,560 | 20,170 | |
Other income | Rs m | 30 | 170 | 200 | 340 | 530 | 150 | 40 | 60 | |
Turnover | Rs m | 20,540 | 18,730 | 20,420 | 20,390 | 20,190 | 19,610 | 20,600 | 20,230 | |
Expenses | Rs m | 14,900 | 13,830 | 14,810 | 14,640 | 14,260 | 13,980 | 13,950 | 13,820 | |
Gross profit | Rs m | 5,610 | 1,160 | 5,410 | 5,410 | 5,400 | 5,480 | 6,610 | 6,350 | |
Depreciation | Rs m | 1,560 | 1,600 | 1,600 | 1,630 | 1,630 | 1,680 | 1,610 | 1,650 | |
Interest | Rs m | 1,330 | 1,230 | 1,220 | 1,160 | 1,110 | 1,020 | 1,020 | 920 | |
Profit before tax | Rs m | 2,750 | -1,500 | 2,790 | 2,960 | 3,190 | 2,930 | 4,020 | 3,840 | |
Tax | Rs m | 290 | 20 | 630 | 520 | 680 | -210 | 810 | 740 | |
Profit after tax | Rs m | 2,460 | -1,520 | 2,160 | 2,440 | 2,510 | 3,140 | 3,210 | 3,100 | |
Gross profit margin | % | 27.4 | 6.3 | 26.8 | 27.0 | 27.5 | 28.2 | 32.1 | 31.5 | |
Effective tax rate | % | 10.5 | -1.3 | 22.6 | 17.6 | 21.3 | -7.2 | 20.1 | 19.3 | |
Net profit margin | % | 12.0 | -8.2 | 10.7 | 12.2 | 12.8 | 16.1 | 15.6 | 15.4 | |
Diluted EPS | Rs | 14.5 | -9.0 | 12.8 | 14.4 | 14.8 | 18.6 | 19.0 | 18.3 | |
Diluted EPS (TTM) | Rs | 48.2 | 25.8 | 28.9 | 32.7 | 33.0 | 60.6 | 66.8 | 70.7 | |
![]() |
Read: Torrent Pharma 2QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ALEMBIC WOCKHARDT PIRAMAL ENTERPRISES AUROBINDO PHARMA UNICHEM LAB
Compare TORRENT PHARMA With: ALEMBIC WOCKHARDT PIRAMAL ENTERPRISES AUROBINDO PHARMA UNICHEM LAB
Compare TORRENT PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More